Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akero Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AKRO
Nasdaq
8731
https://akerotx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akero Therapeutics Inc
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
- Mar 20th, 2024 5:32 pm
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
- Mar 18th, 2024 11:00 am
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
- Mar 15th, 2024 1:30 pm
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
- Mar 14th, 2024 2:40 pm
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Mar 8th, 2024 9:02 pm
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Mar 7th, 2024 9:01 pm
President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
- Mar 7th, 2024 4:54 am
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Mar 6th, 2024 2:13 am
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
- Mar 5th, 2024 7:12 pm
Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Mar 4th, 2024 9:21 pm
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
- Mar 4th, 2024 9:04 pm
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
- Mar 4th, 2024 5:30 pm
Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market
- Mar 4th, 2024 4:59 pm
UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients
- Mar 4th, 2024 11:22 am
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Mar 4th, 2024 11:00 am
Akero strengthens MASH drug’s case with new study data
- Mar 4th, 2024 9:00 am
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
- Mar 1st, 2024 2:55 pm
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
- Feb 29th, 2024 1:00 pm
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 29th, 2024 12:00 pm
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
- Feb 26th, 2024 2:40 pm
Scroll